Table 3.
Clinical characteristics of the high and low ALC group
| Variable, n (%) | high NLR (n = 17) | low NLR (n = 12) | p‐value |
|---|---|---|---|
| Age, median (range), year | 63 (50–72) | 63 (55–76) | 0.298 |
| Gender (male) | |||
| Male | 14 (82.4) | 10 (83.3) | 1.000 |
| Female | 3 (17.6) | 2 (16.7) | |
| Smoking status | |||
| Smoker/ex‐smoker | 13 (76.5) | 8 (66.7) | 0.873 |
| Never smoker | 4 (23.5) | 4 (33.3) | |
| ECOG PS | |||
| 0 | 14 (82.4) | 11 (91.7) | 0.652 |
| 1 | 2 (11.8) | 1 (8.3) | |
| 2 | 1 (5.8) | 0 | |
| Histology | |||
| Adenocarcinoma | 10 (58.8) | 10 (83.3) | 0.318 |
| Non‐adenocarcinoma | 7 (41.2) | 2 (16.7) | |
| Staging | |||
| IIIA | 3 (17.6) | 5 (41.7) | 0.319 |
| IIIB | 13 (76.5) | 6 (50.0) | |
| IIIC | 1 (5.9) | 1 (8.3) | |
| EGFR mutation status | |||
| Mutated EGFR | 2 (11.8) | 2 (16.7) | 1.000 |
| Wild type | 10 (58.8) | 8 (66.6) | |
| Unknown | 5 (29.4) | 2 (16.7) | |
| ALK fusion status | |||
| Positive | 1 (5.9) | 0 | 0.556 |
| Negative | 10 (58.8) | 6 (50.0) | |
| Unknown | 6 (35.3) | 6 (50.0) | |
| PD‐L1 TPS | |||
| Positive (≥1%) | 10 (58.8) | 4 (33.3) | 0.278 |
| Negative (<1%) | 2 (11.8) | 4 (33.3) | |
| Unknown | 5 (29.4) | 4 (33.3) | |
| Chemotherapy regimen | |||
| Docetaxel plus cisplatin | 6 (35.3) | 4 (33.3) | 1.000 |
| Vinorelbine plus cisplatin | 11 (64.7) | 8 (66.7) | |
| Dose of radiotherapy | |||
| 60–66 Gy | 13 (76.5) | 10 (83.3) | 1.000 |
| >66 Gy | 4 (23.5) | 2 (16.7) | |
| Timing of durvalumab initiation post‐CCRT, median (month) | 2.6 (1.2–3.5) | 3.2 (2.5–3.8) |
0.318 |
ALC, absolute lymphocyte count; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; PD‐L1, Programmed death‐ligand 1; TPS, tumor proportion score; CCRT, concurrent chemoradiation.